劲方医药科技（上海）股份有限公司（劲方医药-B，股票代码：02595）最新公告显示，该公司已获董事会批准一项股份购回授权，将最多回购不超过已发行股本（不含库存在内）的10%。截至本次公告基准日，公司已发行股份约3.70亿股，按此估算，此次购回规模最高可达约3703.67万股。
公司方面称，购回所需资金将来自合法可用资金，并根据中国公司法及香港联合交易所有限公司上市规则的相关规定进行。董事会认为，这项购回计划有助于提升股东价值，并有利于公司整体利益。
若该授权在2026年5月11日的股东大会上获批，公司将在授权期间根据市场情况适时执行购回，并于适用法律及规则所允许的范围内对购回股份进行处理。公司同时公告称，将在必要时遵守暂停过户规定并及时通知市场，后续将密切关注市场动态，以确保购回过程符合所有监管要求并维护股东权益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.